vimarsana.com
Home
Live Updates
Genmab A/S: Genmab Announces Submissions of Regulatory Appli
Genmab A/S: Genmab Announces Submissions of Regulatory Appli
Genmab A/S: Genmab Announces Submissions of Regulatory Applications for Epcoritamab (DuoBody-CD3xCD20) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma (LBCL) and Diffuse Large B-Cell Lymphoma (DLBCL)
Genmab has Submitted Biologics License Application (BLA) to U.S. Food and Drug Administration (FDA) for epcoritamab European Medicines Agency (EMA) has validated Marketing Authorization Application
Related Keywords
Copenhagen ,
Køavn ,
Denmark ,
Japan ,
Tokyo ,
New Jersey ,
United States ,
Netherlands ,
Austria ,
Vienna ,
Wien ,
David Freundel ,
Andrew Carlsen ,
Product Communications ,
Macrophage Propertiesj Immunol ,
Twitter ,
Drug Administration ,
Exchange Commission ,
Meeting Of The European Hematology Association ,
Development Of Novel Anti ,
European Medicines Agency ,
Diffuse Large Lymphoma Research Foundation ,
Submitted Biologics License Application ,
Medicines Agency ,
Marketing Authorization Application ,
Biologics License Application ,
Presidential Symposium ,
Annual Meeting ,
European Hematology Association ,
Chief Executive Officer ,
Largeb Cell Lymphoma ,
Diffuse Largeb Cell Lymphoma ,
Media Release ,
Annual Report ,
Y Shaped Genmab ,
Rev Oncol ,
Research Foundation ,
Clinically Utilized ,
Directed Antibodies ,
Macrophage Properties ,
Novel Anti Cd ,
Cell Surface ,
Cancer Sci ,
Media Contact ,
Investor Relations ,
Vice President ,
Genmab ,
Nnounces ,
Submissions ,
Egulatory ,
Applications ,
Epcoritamab ,
Uobody ,
D3xcd20 ,
Treatment ,
Relapsed ,
Refractory ,
Barge ,
Fell ,
Lymphoma ,
Bcl ,
Diffuse ,
Dlbcl ,